combination are largely palliative, and these regimens show increased toxicity. The 5-year relative survival rate for pancreatic cancer in the USA is only 8%. 1 Therefore, there is an urgent need for the development of new therapeutic compounds with low toxicity.
Natural compounds are generally considered to be safe and have been shown to have anti-inflammatory and anticancer effects. Xanthohumol, a prenylated chalcone, is the principal flavonoid found in the hop plant (Humulus lupulus L.). Xanthohumol has been shown to inhibit the growth of different types of human cancer cells, including breast, colon, hepatocellular, ovarian, pancreatic and prostate cancer cells as well as leukemia cells. [6] [7] [8] [9] [10] [11] [12] [13] [14] In addition, xanthohumol has been shown to induce both caspase-dependent and caspase-independent apoptosis 8, 15 and to inhibit invasion 7 and angiogenesis. 16 However, the mechanisms through which xanthohumol mediates these effects are not fully understood. Xanthohumol has been shown to inhibit nuclear factor-kB (NF-jB) activation. 17, 18 In addition, xanthohumol has been shown to have a low toxicity profile and high bioavailability, and orally administered xanthohumol does not affect major organ function in vivo. [19] [20] [21] Nuclear factor-kB is a transcription factor that is associated with cell proliferation, invasion, angiogenesis and metastasis in multiple types of cancer. 22 In pancreatic cancer, NF-jB has also been shown to play a major role in angiogenesis, which is essential for tumor growth and metastasis. 23, 24 In our previous studies, we found that angiogenesis is essential for metastasis of pancreatic cancer to the liver. 25, 26 Moreover, NF-jB has been shown to be constitutively activated in pancreatic cancer cells. 27 These findings suggest that agents inhibiting NF-jB activation could reduce angiogenesis in pancreatic cancer. In previous studies, vascular endothelial growth factor (VEGF) and interleukin-8 (IL-8) have been identified as key mediators of angiogenesis in pancreatic tumors. [28] [29] [30] [31] Indeed, we previously demonstrated that suppression of NF-jB signaling reduces the production of both VEGF and IL-8, which are major angiogenic factors, in pancreatic cancer. 32 However, the effects of xanthohumol in pancreatic cancer have not been clearly elucidated.
In this study, we initially confirmed that low-dose xanthohumol inhibited NF-jB signaling. We next investigated whether xanthohumol suppressed angiogenesis in pancreatic cancer. We found that xanthohumol blocked angiogenesis in pancreatic cancer by reducing both NF-jB activity and consequent production of angiogenic factors, in vitro and in vivo. This is the first report demonstrating the effects of xanthohumol on pancreatic cancer angiogenesis. In addition, our results suggest that xanthohumol may be useful in treating pancreatic cancer.
| MATERIALS AND METHODS

| Reagents
Xanthohumol and DMSO were purchased from Sigma-Aldrich (St.
Louis, MO, USA). Xanthohumol was dissolved in DMSO into stock concentrations of 50 mmol/L. Rabbit monoclonal antibodies against Ki67, NF-jB p65 and VEGF and rabbit polyclonal antibodies against CD31 and IL-8 were purchased from Abcam plc (Cambridge, UK).
Neutralizing monoclonal anti human VEGF and IL-8 antibody were provided by R&D Systems (Abingdon, UK).
| Cell lines and cell culture
The human pancreatic adenocarcinoma cell lines BxPC-3, MIA PaCa-2 and AsPC-1 were obtained from ATCC (Rockville, MD, USA). BxPC-3 and AsPC-1 cells were cultured in Roswell Park
Memorial Institute (RPMI-1640) medium (Sigma Aldrich), and MIA PaCa-2 cells were cultured in DMEM supplemented with 10% FBS, 10 000 U/mL penicillin, 10 mg/mL streptomycin and 25 lg/mL amphotericin B (Sigma Aldrich) in a 37°C humidified incubator with 5% CO 2 .
| Cell proliferation assay
The proliferation assay was performed using a Premix WST-1 Cell
Proliferation Assay System (Takara Bio, Japan) according to the man- were used in the NF-jB activity assay.
| Angiogenesis assay
The influence of VEGF and IL-8 on tube formation by HUVEC in the presence of pancreatic cancer cells was investigated in triplicate using an Angiogenesis Kit (Kurabo, Osaka, Japan) according to the manufacturer's instructions. We cocultured pancreatic cancer cells and fibroblasts using a double chamber method in 24-well plates.
BxPC-3 cells (2 9 10 3 cells) were seeded into transwell chambers and cultured for 1 day; the chambers were then placed into the HUVEC/fibroblast coculture system. The optimized medium was added with various concentrations of xanthohumol (0-1 lmol/L), and medium was refreshed every 3 days. Cells were cultured for 11 days, and the HUVEC tube formation was evaluated as described above.
| Animals
Female BALB/c nu-nu mice (6 weeks old) were purchased from Charles River Laboratories (Sulzbach, Germany 3 , the mice were randomly divided into 2 groups (5 mice per group); mice in group I were not treated, whereas mice in group II were given xanthohumol (10 mg/kg/wk).
We calculated the tumor volume according to the following formula:
tumor volume (mm 
| Xanthohumol inhibited nuclear factor-kB activation in pancreatic cancer cells
To examine the effects of xanthohumol on the activity of NF-jB, we performed Trans AM NF-jB p65/p50 Transcription Factor Assays.
As shown in Figure 1B Figure 5D ).
| Xanthohumol inhibited proliferation and
angiogenesis and reduced the expression of nuclear factor-kB p65, vascular endothelial growth factor and interleukin-8
To determine the effects of xanthohumol on proliferation and angiogenesis, we examined the expression of Ki-67, the cell proliferation marker, and CD31, an MVD marker, in tumor tissue. As shown in Previous studies have shown that most pancreatic cancer cells (approximately 70%) exhibit constitutive activation of NF-jB. 23 Moreover, NF-jB is thought to have an important role in the regulation of apoptosis, oncogenesis and angiogenesis. 23, 33 Indeed, we previously reported that blockade of NF-jB activity by the proteasome inhibitor MG132 inhibited the expression of the pro-angiogenic molecules VEGF and IL-8 and suppressed cancer-induced angiogenesis. 32 These reports were consistent with our results demonstrating that xanthohumol inhibited the expression of VEGF and IL-8 by blocking NF-jB activation in pancreatic cancer.
The aggressive growth and metastasis of solid tumors, including pancreatic cancer, depend on angiogenesis, which is mediated by F I G U R E 1 A, Effects of xanthohumol on the proliferation of pancreatic cancer cell lines. Pancreatic cancer cell lines (BxPC-3, AsPC-1 and MIA PaCa-2) were treated with xanthohumol at the indicated concentrations for 72 h, and cytotoxicity was measured using WST-1 assays.
Values are expressed as means AE SD (n = 6; *P < .05; **P < .01 compared with the control in all cell lines). XN, xanthohumol; C, control. B, C, Xanthohumol inhibited NF-jB activity in pancreatic cancer cell lines. Pancreatic cancer cell lines (BxPC-3, AsPC-1 and MIA PaCa-2) were treated with xanthohumol at the indicated concentrations for 24 h (B) and then stimulated with TNF-a (10 ng/mL) for 30 min (C). The activity of NF-jB in nuclear extracts was measured using Trans AM NF-jB p65/p50 Transcription Factor Assays. Values are expressed as means AE SD (n = 3; *P < .05; **P < .01 compared with the control in all cell lines). XN, xanthohumol angiogenic factors derived from tumor and stromal cells. 
and (D) represent the means AE SD of each group (n = 5; *P < .05, **P < .01 compared with the untreated group). NS, not significant lung injury, peripheral neuropathy, tumor lysis syndrome and myelosuppression). Therefore, it is very difficult to use these drugs in combination with chemotherapies for treating pancreatic cancer. 35, 36 However, because we showed that xanthohumol has few adverse effects, xanthohumol may not be harmful to humans.
Overall, our results showed, for the first time, that xanthohumol inhibited angiogenesis by blocking NF-jB and its downstream targets, leading to the inhibition of angiogenesis, even at low concentrations.
Because low-dose xanthohumol did not block normal physiological function, use of the natural product xanthohumol may be safer and may show reduced toxicity compared with other available treatments.
Therefore, we concluded that xanthohumol may have significant potential as an effective therapy for pancreatic cancer.
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